Transgenomic Q1 Sales Down 69 Percent | GenomeWeb

NEW YORK (GenomeWeb) – Molecular diagnostics firm Transgenomic today reported a sharp drop of 69 percent in first quarter sales reflecting the phasing of contracts due to client sample availability issues, but said that this effect is expected to be "transitory."

For the three-month period ended March 31, Transgenomics' net sales fell to $236,000 from $750,000 the year before. However, the company said it expects the effect causing the drop to be transitory.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.